ROCHE REMAINS A BELLWETHER, DESPITE RECENT (R&D) JITTERS (ADD; 14% UPSIDE)
19/09/22 -" Since early 2022, an already fragile global economy (surfing on monetary excesses) has faced several challenges – spiralling inflation and supply-chain disruptions – due to the war in Europe, ..."
Pages
66
Language
English
Published on
19/09/22
You may also be interested by these reports :
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...